Coripharma
Coripharma is an Iceland-based, privately held European generic pharmaceutical company that develops and manufactures technically challenging oral solid dose generics and out-licenses dossiers and supply to over 50 European pharmaceutical partners across Europe.
- Company typePrivate
- Founded2018
- HeadquartersHafnarfjörður, Iceland
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Coripharma does
Coripharma is a privately held European generic pharmaceutical company headquartered in Hafnarfjörður, Iceland. Founded in 2018 through the acquisition of Icelandic manufacturing assets and vertically integrated in 2019 with the acquisition of on-site R&D operations, Coripharma develops and manufactures technically challenging generic oral solid dose pharmaceuticals (tablets and capsules) at a GMP-approved facility that is operated entirely on renewable geothermal and hydropower energy. By 2025, the portfolio comprises 39 products spanning oncology (Binimetinib, Ponatinib), antiviral therapy (Letermovir), cystic fibrosis (Ivacaftor), ADHD (Lisdexamphetamine) and inflammation (Apremilast), with 16 dossiers completed from its own development since inception.
The commercial model is B2B out-licensing into Europe. Coripharma produces the complete dossier, conducts regulatory submissions, and supplies finished product to over 50 European pharmaceutical partners who commercialize under their own brand names in their respective markets. The dedicated business development team pursues additional out-licensing agreements and manages partner relationships; the offering includes patent landscape analysis, artwork design and reliable GMP manufacturing supply. Day-1 at patent expiry is treated as a core competency, demonstrated by the 17 January 2026 launch of Apremilast in Germany through a local partner immediately following patent expiry, including the production of a multi-strength blister starter pack at the Icelandic site.
Coripharma is led by CEO Jónína Guðmundsdóttir (joined 2020; 20+ years pharma experience, formerly VP at Medis) with a CFO hire from Hansa Biopharma in 2023 and a recently expanded engineering, quality, supply chain, R&D, HR and business development leadership team. The company holds ÍST 85:2012 equal pay certification, an Excellent Workplace Certificate, and an ISO-certified hosting arrangement, and publishes annual sustainability reports; ownership, investors and audited financials are not publicly disclosed.
Coripharma firmographics
Firmographics- Name
- Coripharma
- Legal name
- Coripharma
- Website
- https://coripharma.is
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Coripharma is an Iceland-based, privately held European generic pharmaceutical company that develops and manufactures technically challenging oral solid dose generics and out-licenses dossiers and supply to over 50 European pharmaceutical partners across Europe.
- Ownership category
- akta.pro rank
Coripharma industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
- akta.pro secondary industry
- GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
Keywords
Where Coripharma is headquartered
LocationHeadquarters
- HQ city
- Hafnarfjörður
- HQ country
- Iceland
- HQ region
- Europe
Offices1 record
Markets served
Coripharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- Product Out-licensing: Coripharma develops generic pharmaceutical dossiers and out-licenses them to European partners who commercialize products under their own brand. The company provides complete documentation, regulatory support, and manufactured product supply.
- Contract Manufacturing: Manufacturing and supply of generic pharmaceuticals from GMP-approved Icelandic facility to out-licensing partners across Europe.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Coripharma product offering
Product offeringCore offering
Coripharma develops and manufactures technically challenging generic oral solid dose pharmaceuticals (tablets and capsules) and out-licenses the resulting dossiers, regulatory support, and finished product supply to European pharmaceutical partners who commercialize the medicines under their own brand. Operations are performed in-house at a GMP-approved, renewable-energy-powered facility in Hafnarfjörður, Iceland, covering the full development cycle from formulation and bioequivalence studies through to regulatory submissions and commercial supply.
Product overview
Coripharma is a European generic pharmaceutical company offering an integrated product development and manufacturing platform. The core offering includes Development to Market services (developing technically challenging generic oral solid dose pharmaceuticals) combined with Out-licensing partnerships for European pharmaceutical companies. The company operates a GMP-approved manufacturing facility in Iceland running on 100% renewable energy. The product portfolio spans multiple therapeutic areas including oncology (Binimetinib, Ponatinib), antiviral (Letermovir), cystic fibrosis (Ivacaftor), CNS (Lisdexamphetamine, Apremilast), with 39 products in portfolio and 8 products launched as of 2025. The company provides comprehensive regulatory support, dossier documentation, and reliable manufacturing supply to its out-licensing partners across Europe.
Differentiator
Problem solved
Functional benefit
Products and services
- Development to Market End-to-end development and manufacturing service for technically challenging generic oral solid dose pharmaceuticals (tablets, capsules), targeting high-value, low-volume products where development complexity creates competitive opportunity. Delivered from Coripharma's GMP-approved Icelandic facility with integrated R&D and manufacturing for European out-licensing partners.
- Out-licensing to European Partners B2B out-licensing of Coripharma-developed generic pharmaceutical dossiers to European pharmaceutical partners, including complete regulatory documentation, patent landscape analysis, artwork design, and commercial product supply from the GMP-approved Icelandic facility. Partners commercialize the products under their own brand in their home markets.
- Binimetinib Tablets (generic) Generic oral MEK inhibitor tablet for melanoma treatment (in combination with encorafenib) bioequivalent to the reference product Mektovi. Part of Coripharma's oncology portfolio and offered through out-licensing to European partners.
- Letermovir Tablets (generic) Generic oral antiviral tablet for prophylaxis of cytomegalovirus reactivation. Part of Coripharma's antiviral portfolio and offered through out-licensing to European partners.
- Ponatinib (generic) Generic oncology product used in treatment of certain forms of leukemia, based on reference product Iclusig. Offered through out-licensing to European partners.
- Ivacaftor Tablets (generic) Generic CFTR potentiator tablets for cystic fibrosis treatment, available in 75mg and 150mg strengths, offered through out-licensing to European partners.
- Apremilast (generic) Generic Apremilast launched in Germany on Day-1 of patent expiry with a first-of-its-kind multi-strength starter pack blister presentation. Launched in collaboration with a German partner and supported across additional European countries.
- Lisdexamphetamine (generic) Generic CNS product for ADHD management based on reference product Elvanse; the 16th dossier completed from Coripharma's own development and offered through out-licensing to European partners.
Quantifiable outcome
- Day-1 patent launch achieved for Apremilast in Germany
- +2 more outcomes
Companies that use Coripharma
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles1 record
Coripharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Coripharma partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and supporting.
- German Partner (Apremilast)coreClose collaboration with German pharmaceutical partner for successful Day-1 patent launch of Apremilast in Germany. Coripharma also supported rollout in other countries, adding further presence within the European market. This represents an important milestone in Coripharma's European commercial activities.
- KlappirsupportingPartnership with Klappir, a smart sustainability platform, for measuring and reducing carbon footprint across all business activities. Through this partnership, Coripharma tracks environmental metrics and works toward sustainability goals.
- European Pharmaceutical Partners (50+ companies)coreCoripharma has signed with over 50 pharmaceutical companies including major European players for out-licensing partnerships. These partners receive dossiers, regulatory support, and manufactured products for commercialization across European markets.
Scale indicators9 records
Recent moves7 records
Expansion highlights5 records
Coripharma competitors and assessment
Company assessmentBroad incumbents
- Krka: Slovenian-headquartered European generic manufacturer with vertically integrated development and manufacturing and growing presence in technically demanding generics. Comparable end-market and partner model, though at substantially larger scale.
- Polpharma: European generics leader with integrated development, dossier, and manufacturing capabilities across multiple dosage forms. Comparable strategy of targeting Central and broader European markets with out-licensing and supply partnerships.
- Sandoz: Global generic and biosimilar leader spun out of Novartis, with deep European dossier development and manufacturing scale. Relevant overlap with Coripharma across European out-licensing partnerships and complex generic selection.
- Stada Arzneimittel: Large European generic and specialty pharma incumbent with a broad generic portfolio and significant out-licensing activity. Overlaps with Coripharma in technically challenging generics and European out-licensing channels, but at much greater scale and breadth.
- Teva Pharmaceutical Industries: World's largest generic manufacturer with substantial European dossier and out-licensing footprint. Increasingly competing for technically challenging generics where Coripharma currently differentiates.
- Apotex: Canadian-headquartered generic manufacturer with established European presence and dossier/supply operations. Comparable focus on out-licensing dossiers and finished-dose supply to regional partners.
- Aurobindo Pharma: Indian-headquartered global generic manufacturer expanding aggressively in European complex generics, including oncology and CNS — the same therapeutic categories Coripharma is targeting. Represents the most active price-competition threat.
Direct peers
- Medis: European-focused specialty generic pharmaceutical company with a similar out-licensing and dossier-supply model in technically challenging generics. Direct comparability: Coripharma's CEO and several directors (Commercial Operations, Supply Chain) were previously senior leaders at Medis, indicating closely matched operating playbooks.
- Alvogen: Out-licensing and specialty generic player with strong European footprint and operations touching Iceland. Coripharma's CFO Ludvik Karl Tomasson was previously at Alvogen, underscoring operational overlap in dossier development, partner commercial models, and complex-generics strategy.
Regional players
- Gedeon Richter: Hungary-based European generic pharmaceutical company with integrated R&D and manufacturing, focused on Central and Eastern European markets with growing Western European out-licensing activity. Comparable vertical integration and specialty-generics portfolio strategy.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Coripharma social profiles
Digital presenceCoripharma compliance and trust
Trust signalCompliance4 records
Coripharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Coripharma leadership team
Management profileNumber of profiles
Profiles9 records
Coripharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Coripharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Coripharma
What does Coripharma do?
Coripharma develops and manufactures technically challenging generic oral solid dose pharmaceuticals (tablets and capsules) and out-licenses the resulting dossiers, regulatory support, and finished product supply to European pharmaceutical partners who commercialize the medicines under their own brand. Operations are performed in-house at a GMP-approved, renewable-energy-powered facility in Hafnarfjörður, Iceland, covering the full development cycle from formulation and bioequivalence studies through to regulatory submissions and commercial supply.
Is Coripharma a public or private company?
Coripharma is a private company. It is classified as unknown and is currently operating.
When was Coripharma founded?
Coripharma was founded in 2018. It employs 101 to 250 people.
Where is Coripharma based?
Coripharma is headquartered in Hafnarfjörður, Iceland, in the Europe region.
How does Coripharma make money?
Two revenue lines are on record. Product Out-licensing is the primary driver. The others are contract Manufacturing.
Who are Coripharma's main competitors?
Broad incumbents on record are Krka, Polpharma, Sandoz, Stada Arzneimittel, Teva Pharmaceutical Industries, Apotex and Aurobindo Pharma. Direct peers are Medis and Alvogen. Gedeon Richter is listed as a regional player.
Does Coripharma have an API?
No public API is recorded for Coripharma.
What industry is Coripharma in?
Coripharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development), with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 325412 and its SIC code is 8731.